Near-infrared Fluorescence Lymphatic Imaging Assessment of Lymphatic Response to Pneumatic Back/Neck Lymphatic Drainage Delivered by a Pneumatic Manual Lymphatic Drainage Device
- Conditions
- Neck PainBack Pain
- Interventions
- Drug: Indocyanine green (ICG) dyeDevice: NIRF-LI imagingDevice: Neuroglide pad
- Registration Number
- NCT05946837
- Brief Summary
The purpose of this study is to objectively assess lymphatic function before, during, and immediately after Neuroglide treatment in lower trunk and leg lymphatic vessels, torso, axillary regions, inguinal regions, upper extremities, and cervical/neck and to determine any VAS (Visual Analog Scale, a commonly used measure of pain perception) score change after Neuroglide treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4
- ambulatory and possess all four limbs
- Female participants of childbearing potential must have a negative urine pregnancy test within 36 hours prior to study drug administration
- Female participants of childbearing potential must agree to use a medically accepted method of contraception for a period of one month following each imaging session in the study
- Weight less than 400 lbs
- Women who are pregnant or breast-feeding
- Persons who are allergic to iodine or indocyanine green
- Heart failure, poorly controlled kidney disease (glomerular filtration rate <30 mls per minute), hypoproteinemia, pulmonary hypertension, or hypothyroidism
- Any circumstance where increased lymphatic or venous return is undesirable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Pneumatic Compression Therapy (PCT) NIRF-LI imaging - Pneumatic Compression Therapy (PCT) Indocyanine green (ICG) dye - Pneumatic Compression Therapy (PCT) Neuroglide pad -
- Primary Outcome Measures
Name Time Method Change in frequency of lymphatic pulsing as assessed by the number of lymphatic pulses per minute in each region imaged Baseline, during Neuroglide treatment ( 1 hour after NIRF-LI imaging ), 1 hour after PCT treatment
- Secondary Outcome Measures
Name Time Method Change in pain as assessed by the Visual Analog Scale (VAS) Baseline, 1 hour after PCT treatment, 4-8 weeks after imaging for data analysis completion This is scored from 1(no pain)-10( worst pain possible) a higher number indicating more pain
Trial Locations
- Locations (1)
The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States